Potential role of probiotics in the management of gastric ulcer (Review)

Khoder,Ghalia; Al‑Menhali,Asma  A.; Al‑Yassir,Farah; Karam,Sherif  M.

doi:10.3892/etm.2016.3293

Potential role of probiotics in the management of gastric ulcer (Review)

Authors:
- Ghalia Khoder
- Asma A. Al‑Menhali
- Farah Al‑Yassir
- Sherif M. Karam
View Affiliations

Affiliations: Department of Pharmaceutics and Pharmaceutical Technology, College of Pharmacy, University of Sharjah, Sharjah 27272, United Arab Emirates, Department of Biology, College of Science, United Arab Emirates University, Al‑Ain 17666, United Arab Emirates, Department of Anatomy, College of Medicine and Health Sciences, United Arab Emirates University, Al‑Ain 17666, United Arab Emirates
Published online on: April 26, 2016 https://doi.org/10.3892/etm.2016.3293
Pages: 3-17
Copyright: © Khoder et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Gastric ulcer is one of the most common chronic gastrointestinal diseases characterized by a significant defect in the mucosal barrier. Helicobacter pylori (H. pylori) infection and the frequent long‑term use of non-steroidal anti‑inflammatory drugs are major factors involved in gastric ulcer development. Acid inhibitors and antibiotics are commonly used to treat gastric ulcer. However, in the last few decades, the accumulating evidence for resistance to antibiotics and the side effects of antibiotics and acid inhibitors have drawn attention to the possible use of probiotics in the prevention and treatment of gastric ulcer. Probiotics are live microorganisms that when administered in adequate amounts confer health benefits on the host. Currently, the available experimental and clinical studies indicate that probiotics are promising for future applications in the management of gastric ulcers. This review aims to provide an overview of the general health benefits of probiotics on various systemic and gastrointestinal disorders with a special focus on gastric ulcer and the involved cellular and molecular mechanisms: i) Protection of gastric mucosal barrier; ii) upregulation of prostaglandins, mucus, growth factors and anti‑inflammatory cytokines; iii) increased cell proliferation to apoptosis ratio; and iv) induction of angiogenesis. Finally, some of the available data on the possible use of probiotics in H. pylori eradication are discussed.

View Figures

View References

1.	Tarnawski A, Ahluwalia A and Jones MK: Gastric cytoprotection beyond prostaglandins: Cellular and molecular mechanisms of gastroprotective and ulcer healing actions of antacids. Curr Pharm Des. 19:126–132. 2013. View Article : Google Scholar : PubMed/NCBI
2.	Lau JY, Barkun A, Fan DM, Kuipers EJ, Yang YS and Chan FK: Challenges in the management of acute peptic ulcer bleeding. Lancet. 381:2033–2043. 2013. View Article : Google Scholar : PubMed/NCBI
3.	Hwang JJ, Lee DH, Lee AR, Yoon H, Shin CM, Park YS and Kim N: Characteristics of gastric cancer in peptic ulcer patients with Helicobacter pylori infection. World J Gastroenterol. 21:4954–4960. 2015. View Article : Google Scholar : PubMed/NCBI
4.	Taş İ, Ülger BV, Önder A, Kapan M and Bozdağ Z: Risk factors influencing morbidity and mortality in perforated peptic ulcer disease. Ulus Cerrahi Derg. 31:20–25. 2014.PubMed/NCBI
5.	Malfertheiner P: Helicobacter pylori infection-management from a European perspective. Dig Dis. 32:275–280. 2014. View Article : Google Scholar : PubMed/NCBI
6.	Wallace JL, Syer S, Denou E, de Palma G, Vong L, McKnight W, Jury J, Bolla M, Bercik P, Collins SM, et al: Proton pump inhibitors exacerbate NSAID-induced small intestinal injury by inducing dysbiosis. Gastroenterology. 141:1314–1322.e5. 2011. View Article : Google Scholar : PubMed/NCBI
7.	Karam SM and Forte JG: Inhibiting gastric H(+)-K(+)-ATPase activity by omeprazole promotes degeneration and production of parietal cells. Am J Physiol. 266:G745–G758. 1994.PubMed/NCBI
8.	Ghotaslou R, Leylabadlo HE and Asl YM: Prevalence of antibiotic resistance in Helicobacter pylori: A recent literature review. World J Methodol. 5:164–174. 2015. View Article : Google Scholar : PubMed/NCBI
9.	Howden CW, Chey WD and Vakil NB: Clinical rationale for confirmation testing after treatment of Helicobacter pylori infection: Implications of rising antibiotic resistance. Gastroenterol Hepatol (NY). 10(7 Suppl 3): S1–S19. 2014.
10.	Tarnawski A, Hollander D, Krause WJ, Dabros W, Stachura J and Gergely H: ‘Healed’ experimental gastric ulcers remain histologically and ultrastructurally abnormal. J Clin Gastroenterol. 12(Suppl 1): S139–S147. 1990. View Article : Google Scholar : PubMed/NCBI
11.	Watanabe T, Higuchi K, Tominaga K, Fujiwara Y and Arakawa T: Acid regulates inflammatory response in a rat model of induction of gastric ulcer recurrence by interleukin 1beta. Gut. 48:774–781. 2001. View Article : Google Scholar : PubMed/NCBI
12.	Arakawa T, Watanabe T, Tanigawa T, Tominaga K, Fujiwara Y and Morimoto K: Quality of ulcer healing in gastrointestinal tract: Its pathophysiology and clinical relevance. World J Gastroenterol. 18:4811–4822. 2012. View Article : Google Scholar : PubMed/NCBI
13.	Groenen MJ, Kuipers EJ, Hansen BE and Ouwendijk RJ: Incidence of duodenal ulcers and gastric ulcers in a Western population: Back to where it started. Can J Gastroenterol. 23:604–608. 2009. View Article : Google Scholar : PubMed/NCBI
14.	Sung JJ, Kuipers EJ and El-Serag HB: Systematic review: The global incidence and prevalence of peptic ulcer disease. Aliment Pharmacol Ther. 29:938–946. 2009. View Article : Google Scholar : PubMed/NCBI
15.	Fujino S, Suzuki Y and Tanaka T: Cost-benefit analysis of medicinal treatment for gastric ulcers. Long-term model including healing and recurrence. Health Policy. 5:45–72. 1985. View Article : Google Scholar : PubMed/NCBI
16.	Malfertheiner P, Chan FK and McColl KE: Peptic ulcer disease. Lancet. 374:1449–1461. 2009. View Article : Google Scholar : PubMed/NCBI
17.	Hirayama F, Takagi S, Kusuhara H, Iwao E, Yokoyama Y and Ikeda Y: Induction of gastric ulcer and intestinal metaplasia in mongolian gerbils infected with Helicobacter pylori. J Gastroenterol. 31:755–757. 1996. View Article : Google Scholar : PubMed/NCBI
18.	Wang GZ, Huang GP, Yin GL, Zhou G, Guo CJ, Xie CG, Jia BB and Wang JF: Aspirin can elicit the recurrence of gastric ulcer induced with acetic acid in rats. Cell Physiol Biochem. 20:205–212. 2007.PubMed/NCBI
19.	Hammadi M, Adi M, John R, Khoder GA and Karam SM: Dysregulation of gastric H,K-ATPase by cigarette smoke extract. World J Gastroenterol. 15:4016–4022. 2009. View Article : Google Scholar : PubMed/NCBI
20.	Tarnawski AS: Cellular and molecular mechanisms of gastrointestinal ulcer healing. Dig Dis Sci. 50(Suppl 1): S24–S33. 2005. View Article : Google Scholar : PubMed/NCBI
21.	Tarnawski A, Szabo IL, Husain SS and Soreghan B: Regeneration of gastric mucosa during ulcer healing is triggered by growth factors and signal transduction pathways. J Physiol Paris. 95:337–344. 2001. View Article : Google Scholar : PubMed/NCBI
22.	Tarnawski AS and Ahluwalia A: Molecular mechanisms of epithelial regeneration and neovascularization during healing of gastric and esophageal ulcers. Curr Med Chem. 19:16–27. 2012. View Article : Google Scholar : PubMed/NCBI
23.	Okamoto R, Yajima T, Yamazaki M, Kanai T, Mukai M, Okamoto S, Ikeda Y, Hibi T, Inazawa J and Watanabe M: Damaged epithelia regenerated by bone marrow-derived cells in the human gastrointestinal tract. Nat Med. 8:1011–1017. 2002. View Article : Google Scholar : PubMed/NCBI
24.	Karam SM: Lineage commitment and maturation of epithelial cells in the gut. Front Biosci. 4:D286–D298. 1999. View Article : Google Scholar : PubMed/NCBI
25.	Helander HF and Poorkhalkali N: Parietal cell density during gastric ulcer healing in the rat. Scand J Gastroenterol. 39:20–26. 2004. View Article : Google Scholar : PubMed/NCBI
26.	Farrell JJ, Taupin D, Koh TJ, Chen D, Zhao CM, Podolsky DK and Wang TC: TFF2/SP-deficient mice show decreased gastric proliferation, increased acid secretion, and increased susceptibility to NSAID injury. J Clin Invest. 109:193–204. 2002. View Article : Google Scholar : PubMed/NCBI
27.	Liu L, Chiu PW, Lam PK, Poon CC, Lam CC, Ng EK and Lai PB: Effect of local injection of mesenchymal stem cells on healing of sutured gastric perforation in an experimental model. Br J Surg. 102:e158–e168. 2015. View Article : Google Scholar : PubMed/NCBI
28.	Chang Q, Yan L, Wang CZ, Zhang WH, Hu YZ and Wu BY: In vivo transplantation of bone marrow mesenchymal stem cells accelerates repair of injured gastric mucosa in rats. Chin Med J (Engl). 125:1169–1174. 2012.PubMed/NCBI
29.	Maemura T, Shin M and Kinoshita M: Tissue engineering of the stomach. J Surg Res. 183:285–295. 2013. View Article : Google Scholar : PubMed/NCBI
30.	Sato T and Clevers H: SnapShot: Growing organoids from stem cells. Cell. 161:1700–1700.e1. 2015. View Article : Google Scholar : PubMed/NCBI
31.	Pulikkot S, Greish YE, Mourad AH and Karam SM: Establishment of a three-dimensional culture system of gastric stem cells supporting mucous cell differentiation using microfibrous polycaprolactone scaffolds. Cell Prolif. 47:553–563. 2014. View Article : Google Scholar : PubMed/NCBI
32.	Elliott SN, Buret A, McKnight W, Miller MJ and Wallace JL: Bacteria rapidly colonize and modulate healing of gastric ulcers in rats. Am J Physiol. 275:G425–G432. 1998.PubMed/NCBI
33.	Podolsky SH: Metchnikoff and the microbiome. Lancet. 380:1810–1811. 2012. View Article : Google Scholar : PubMed/NCBI
34.	Lilly DM and Stillwell RH: Probiotics: Growth-promoting factors produced by microorganisms. Science. 147:747–748. 1965. View Article : Google Scholar : PubMed/NCBI
35.	Hill C, Guarner F, Reid G, Gibson GR, Merenstein DJ, Pot B, Morelli L, Canani RB, Flint HJ, Salminen S, et al: Expert consensus document. The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic. Nat Rev Gastroenterol Hepatol. 11:506–514. 2014. View Article : Google Scholar : PubMed/NCBI
36.	Wallace TC, Guarner F, Madsen K, Cabana MD, Gibson G, Hentges E and Sanders ME: Human gut microbiota and its relationship to health and disease. Nutr Rev. 69:392–403. 2011. View Article : Google Scholar : PubMed/NCBI
37.	Bezkorovainy A: Probiotics: Determinants of survival and growth in the gut. AmJ Clin Nutr. 73(Suppl 2): S399–S405. 2001.
38.	Isolauri E, Sütas Y, Kankaanpää P, Arvilommi H and Salminen S: Probiotics: Effects on immunity. Am J Clin Nutr. 73(Suppl 2): S444–S450. 2001.
39.	Hong WS, Chen YP and Chen MJ: The antiallergic effect of kefir lactobacilli. J Food Sci. 75:H244–H253. 2010. View Article : Google Scholar : PubMed/NCBI
40.	Cain AM and Karpa KD: Clinical utility of probiotics in inflammatory bowel disease. Altern Ther Health Med. 17:72–79. 2011.PubMed/NCBI
41.	Shyu PT, Oyong GG and Cabrera EC: Cytotoxicity of probiotics from Philippine commercial dairy products on cancer cells and the effect on expression of cfos and cjun early apoptotic-promoting genes and interleukin-1β and tumor necrosis factor-α proinflammatory cytokine genes. Biomed Res Int. 2014:4917402014. View Article : Google Scholar : PubMed/NCBI
42.	Lam EK, Yu L, Wong HP, Wu WK, Shin VY, Tai EK, So WH, Woo PC and Cho CH: Probiotic Lactobacillus rhamnosus GG enhances gastric ulcer healing in rats. Eur J Pharmacol. 565:171–179. 2007. View Article : Google Scholar : PubMed/NCBI
43.	Uchida M and Kurakazu K: Yogurt containing Lactobacillus gasseri OLL2716 exerts gastroprotective action against acute gastric lesion and antral ulcer in rats. J Pharmacol Sci. 96:84–90. 2004. View Article : Google Scholar : PubMed/NCBI
44.	Uchida M, Shimizu K and Kurakazu K: Yogurt containing Lactobacillus gasseri OLL 2716 (LG21 yogurt) accelerated the healing of acetic acid-induced gastric ulcer in rats. Biosci Biotechnol Biochem. 74:1891–1894. 2010. View Article : Google Scholar : PubMed/NCBI
45.	Singh PK and Kaur IP: Synbiotic (probiotic and ginger extract) loaded floating beads: A novel therapeutic option in an experimental paradigm of gastric ulcer. J Pharm Pharmacol. 64:207–217. 2012. View Article : Google Scholar : PubMed/NCBI
46.	Singh PK, Deol PK and Kaur IP: Entrapment of Lactobacillus acidophilus into alginate beads for the effective treatment of cold restraint stress induced gastric ulcer. Food Funct. 3:83–90. 2012. View Article : Google Scholar : PubMed/NCBI
47.	Dharmani P, De Simone C and Chadee K: The probiotic mixture VSL#3 accelerates gastric ulcer healing by stimulating vascular endothelial growth factor. PLoS One. 8:586712013. View Article : Google Scholar
48.	Lam EK, Tai EK, Koo MW, Wong HP, Wu WK, Yu L, So WH, Woo PC and Cho CH: Enhancement of gastric mucosal integrity by Lactobacillus rhamnosus GG. Life Sci. 80:2128–2136. 2007. View Article : Google Scholar : PubMed/NCBI
49.	Timmerman HM, Koning CJ, Mulder L, Rombouts FM and Beynen AC: Monostrain, multistrain and multispecies probiotics - A comparison of functionality and efficacy. Int J Food Microbiol. 96:219–233. 2004. View Article : Google Scholar : PubMed/NCBI
50.	Flatley EA, Wilde AM and Nailor MD: Saccharomyces boulardii for the prevention of hospital onset Clostridium difficile infection. J Gastrointestin Liver Dis. 24:21–24. 2015.PubMed/NCBI
51.	Girard P, Coppé MC, Pansart Y and Gillardin JM: Gastroprotective effect of Saccharomyces boulardii in a rat model of ibuprofen-induced gastric ulcer. Pharmacology. 85:188–193. 2010. View Article : Google Scholar : PubMed/NCBI
52.	Sakarya S and Gunay N: Saccharomyces boulardii expresses neuraminidase activity selective for α2,3-linked sialic acid that decreases Helicobacter pylori adhesion to host cells. APMIS. 122:941–950. 2014. View Article : Google Scholar : PubMed/NCBI
53.	Aragon G, Graham DB, Borum M and Doman DB: Probiotic therapy for irritable bowel syndrome. Gastroenterol Hepatol (NY). 6:39–44. 2010.
54.	Brenner DM, Moeller MJ, Chey WD and Schoenfeld PS: The utility of probiotics in the treatment of irritable bowel syndrome: A systematic review. Am J Gastroenterol. 104:1033–1050. 2009. View Article : Google Scholar : PubMed/NCBI
55.	Moayyedi P, Ford AC, Talley NJ, Cremonini F, Foxx-Orenstein AE, Brandt LJ and Quigley EM: The efficacy of probiotics in the treatment of irritable bowel syndrome: A systematic review. Gut. 59:325–332. 2010. View Article : Google Scholar : PubMed/NCBI
56.	Ki Cha B, Mun Jung S, Hwan Choi C, Song ID, Woong Lee H, Joon Kim H, Hyuk J, Kyung Chang S, Kim K, Chung WS and Seo JG: The effect of a multispecies probiotic mixture on the symptoms and fecal microbiota in diarrhea-dominant irritable bowel syndrome: A randomized, double-blind, placebo-controlled trial. J Clin Gastroenterol. 46:220–227. 2012. View Article : Google Scholar : PubMed/NCBI
57.	Lyra A, Krogius-Kurikka L, Nikkilä J, Malinen E, Kajander K, Kurikka K, Korpela R and Palva A: Effect of a multispecies probiotic supplement on quantity of irritable bowel syndrome-related intestinal microbial phylotypes. BMC Gastroenterol. 10:1102010. View Article : Google Scholar : PubMed/NCBI
58.	Fuochi V, Petronio GP, Lissandrello E and Furneri PM: Evaluation of resistance to low pH and bile salts of human Lactobacillus spp. isolates. Int J Immunopathol Pharmacol. 28:426–433. 2015. View Article : Google Scholar : PubMed/NCBI
59.	Pochart P, Marteau P, Bouhnik Y, Goderel I, Bourlioux P and Rambaud JC: Survival of bifidobacteria ingested via fermented milk during their passage through the human small intestine: An in vivo study using intestinal perfusion. Am J Clin Nutr. 55:78–80. 1992.PubMed/NCBI
60.	Lankaputhra WEV and Shah NP: Survival of Lactobacillus acidophilus and Bifidobacterium in the presence of acid and bile salts. Cult Dairy Prod J. 30:2–7. 1995.
61.	Costello M: Probiotic foods. Foodpro-93: International Food Processing Machinery and Technology Exhibition and Conference (Australia). Sydney Convention & Exhibition Centre. July 12–14–1993.
62.	Clark PA, Cotton LN and Martin JH: Selection of Bifidobacterium spp. for use as dietary adjuncts in cultured dairy foods: II. Tolerance to simulated pH of human stomachs. Cult Dairy Prod J. 28:11–14. 1993.
63.	Jacobsen CN, Rosenfeldt Nielsen V, Hayford AE, Møller PL, Michaelsen KF, Paerregaard A, Sandström B, Tvede M and Jakobsen M: Screening of probiotic activities of forty-seven strains of Lactobacillus spp. by in vitro techniques and evaluation of the colonization ability of five selected strains in humans. Appl Environ Microbiol. 11:4949–4956. 1999.
64.	Lick S, Drescher K and Heller JK: Survival of Lactobacillus delbrueckii subsp. bulgaricus and Streptococcus thermophilus in the terminal ileum of fistulated Göttingen minipigs. Appl Environ Microbiol. 67:4137–4143. 2001. View Article : Google Scholar : PubMed/NCBI
65.	Cotter PD and Hill C: Surviving the acid test: Responses of gram-positive bacteria to low pH. Microbiol Mol Biol Rev. 67:429–453. 2003. View Article : Google Scholar : PubMed/NCBI
66.	Fortier LC, Tourdot-Maréchal R, Diviès C, Lee BH and Guzzo J: Induction of Oenococcus oeni H⁺-ATPase activity and mRNA transcription under acidic conditions. FEMS Microbiol Lett. 222:165–169. 2003. View Article : Google Scholar : PubMed/NCBI
67.	Rius N, Solé M, Francis A and Lorén JG: Buffering capacity and membrane H⁺ conductance of lactic acid bacteria. FEMS Microbiol Lett. 120:291–296. 1994. View Article : Google Scholar
68.	Charalampopoulos D, Pandiella SS and Webb C: Evaluation of the effect of malt, wheat and barley extracts on the viability of potentially probiotic lactic acid bacteria under acidic conditions. Int J Food Microbiol. 82:133–141. 2003. View Article : Google Scholar : PubMed/NCBI
69.	Corcoran BM, Stanton C, Fitzgerald GF and Ross RP: Survival of probiotic lactobacilli in acidic environments is enhanced in the presence of metabolizable sugars. Appl Environ Microbiol. 71:3060–3067. 2005. View Article : Google Scholar : PubMed/NCBI
70.	Haghshenas B, Abdullah N, Nami Y, Radiah D, Rosli R and Yari Khosroushahi A: Microencapsulation of probiotic bacteria Lactobacillus plantarum 15HN using alginate-psyllium-fenugreek polymeric blends. J Appl Microbiol. 118:1048–1057. 2015. View Article : Google Scholar : PubMed/NCBI
71.	Chen S, Zhao Q, Ferguson LR, Shu Q, Weir I and Garg S: Development of a novel probiotic delivery system based on microencapsulation with protectants. Appl Microbiol Biotechnol. 93:1447–1457. 2012. View Article : Google Scholar : PubMed/NCBI
72.	Kailasapathy K: Microencapsulation of probiotic bacteria: Technology and potential applications. Curr Issues Intest Microbiol. 3:39–48. 2002.PubMed/NCBI
73.	Villena MJ, Lara-Villoslada F, Martínez MA and Hernández ME: Development of gastro-resistant tablets for the protection and intestinal delivery of Lactobacillus fermentum CECT 5716. Int J Pharm. 487:314–319. 2015. View Article : Google Scholar : PubMed/NCBI
74.	Mei L, He F, Zhou RQ, Wu CD, Liang R, Xie R, Ju XJ, Wang W and Chu LY: Novel intestinal-targeted Ca-alginate-based carrier for pH-responsive protection and release of lactic acid bacteria. ACS Appl Mater Interfaces. 6:5962–5970. 2014. View Article : Google Scholar : PubMed/NCBI
75.	Zhao Q, Lee SJ, Mutukumira AN, Maddox I and Shu Q: Viability and delivery of immobilised Lactobacillus reuteri DPC16 within calcium alginate gel systems during sequential passage through simulated gastrointestinal fluids. Benef Microbes. 2:129–138. 2011. View Article : Google Scholar : PubMed/NCBI
76.	Adams CA: The probiotic paradox: Live and dead cells are biological response modifiers. Nutr Res Rev. 23:37–46. 2010. View Article : Google Scholar : PubMed/NCBI
77.	Sashihara T, Sueki N and Ikegami S: An analysis of the effectiveness of heat-killed lactic acid bacteria in alleviating allergic diseases. J Dairy Sci. 89:2846–2855. 2006. View Article : Google Scholar : PubMed/NCBI
78.	Zhang L, Nan L, Caicedo R and Neu J: Alive and dead Lactobacillus rhamnosus GG decrease tumor necrosis factor-alpha-induced interleukin-8 production in Caco-2 cells. J Nutr. 135:1752–1756. 2005.PubMed/NCBI
79.	Taverniti V and Guglielmetti S: The immunomodulatory properties of probiotic microorganisms beyond their viability (ghost probiotics: Proposal of paraprobiotic concept). Genes Nutr. 6:261–274. 2011. View Article : Google Scholar : PubMed/NCBI
80.	Sakai Y, Tsukahara T, Bukawa W, Matsubara N and Ushida K: Cell preparation of Enterococcus faecalis strain EC-12 prevents vancomycin-resistant enterococci colonization in the cecum of newly hatched chicks. Poult Sci. 85:273–277. 2006. View Article : Google Scholar : PubMed/NCBI
81.	Marin ML, Lee JH, Murtha J, Ustunol Z and Pestka JJ: Differential cytokine production in clonal macrophage and T-cell lines cultured with bifidobacteria. J Dairy Sci. 80:2713–2720. 1997. View Article : Google Scholar : PubMed/NCBI
82.	Wagner RD, Pierson C, Warner T, Dohnalek M, Hilty M and Balish E: Probiotic effects of feeding heat-killed Lactobacillus acidophilus and Lactobacillus casei to Candida albicans-colonized immunodeficient mice. J Food Prot. 63:638–644. 2000.PubMed/NCBI
83.	Rachmilewitz D, Katakura K, Karmeli F, Hayashi T, Reinus C, Rudensky B, Akira S, Takeda K, Lee J, Takabayashi K and Raz E: Toll-like receptor 9 signaling mediates the anti-inflammatory effects of probiotics in murine experimental colitis. Gastroenterology. 126:520–528. 2004. View Article : Google Scholar : PubMed/NCBI
84.	Orlando A, Refolo MG, Messa C, Amati L, Lavermicocca P, Guerra V and Russo F: Antiproliferative and proapoptotic effects of viable or heat-killed Lactobacillus paracasei IMPC2.1 and Lactobacillus rhamnosus GG in HGC-27 gastric and DLD-1 colon cell lines. Nutr Cancer. 64:1103–1111. 2012. View Article : Google Scholar : PubMed/NCBI
85.	Sanders ME, Guarner F, Guerrant R, Holt PR, Quigley EM, Sartor RB, Sherman PM and Mayer EA: An update on the use and investigation of probiotics in health and disease. Gut. 62:787–796. 2013. View Article : Google Scholar : PubMed/NCBI
86.	Marchesi JR, Adams DH, Fava F, Hermes GD, Hirschfield GM, Hold G, Quraishi MN, Kinross J, Smidt H, Tuohy KM, et al: The gut microbiota and host health: A new clinical frontier. Gut. 65:330–339. 2016. View Article : Google Scholar : PubMed/NCBI
87.	Kumar M, Nagpal R, Kumar R, Hemalatha R, Verma V, Kumar A, Chakraborty C, Singh B, Marotta F, Jain S and Yadav H: Cholesterol-lowering probiotics as potential biotherapeutics for metabolic diseases. Exp Diabetes Res. 2012:9029172012. View Article : Google Scholar : PubMed/NCBI
88.	Tsai TY, Chen LY and Pan TM: Effect of probiotic-fermented, genetically modified soy milk on hypercholesterolemia in hamsters. J Microbiol Immunol Infect. 47:1–8. 2014. View Article : Google Scholar : PubMed/NCBI
89.	Pereira DI and Gibson GR: Cholesterol assimilation by lactic acid bacteria and bifidobacteria isolated from the human gut. Appl Environ Microbiol. 68:4689–4693. 2002. View Article : Google Scholar : PubMed/NCBI
90.	Kadooka Y, Sato M, Imaizumi K, Ogawa A, Ikuyama K, Akai Y, Okano M, Kagoshima M and Tsuchida T: Regulation of abdominal adiposity by probiotics (Lactobacillus gasseri SBT2055) in adults with obese tendencies in a randomized controlled trial. Eur J Clin Nutr. 64:636–643. 2010. View Article : Google Scholar : PubMed/NCBI
91.	Yoda K, Sun X, Kawase M, Kubota A, Miyazawa K, Harata G, Hosoda M, Hiramatsu M, He F and Zemel MB: A combination of probiotics and whey proteins enhances anti-obesity effects of calcium and dairy products during nutritional energy restriction in aP2-agouti transgenic mice. Br J Nutr. 113:1689–1696. 2015. View Article : Google Scholar : PubMed/NCBI
92.	Kim SH, Huh CS, Choi ID, Jeong JW, Ku HK, Ra JH, Kim TY, Kim GB, Sim JH and Ahn YT: The anti-diabetic activity of Bifidobacterium lactis HY8101 in vitro and in vivo. J Appl Microbiol. 117:834–845. 2014. View Article : Google Scholar : PubMed/NCBI
93.	Moroti C, Souza Magri LF, de Rezende Costa M, Cavallini DC and Sivieri K: Effect of the consumption of a new symbiotic shake on glycemia and cholesterol levels in elderly people with type 2 diabetes mellitus. Lipids Health Dis. 11:292012. View Article : Google Scholar : PubMed/NCBI
94.	Huang Y, Wang J, Quan G, Wang X, Yang L and Zhong L: Lactobacillus acidophilus ATCC 4356 prevents atherosclerosis via inhibition of intestinal cholesterol absorption in apolipoprotein E-knockout mice. Appl Environ Microbiol. 80:7496–7504. 2014. View Article : Google Scholar : PubMed/NCBI
95.	Aihara K, Kajimoto O, Hirata H, Takahashi R and Nakamura Y: Effect of powdered fermented milk with Lactobacillus helveticus on subjects with high-normal blood pressure or mild hypertension. J Am Coll Nutr. 24:257–265. 2005. View Article : Google Scholar : PubMed/NCBI
96.	Rashid SK, Idris-Khodja N, Auger C, Alhosin M, Boehm N, Oswald-Mammosser M and Schini-Kerth VB: Probiotics (VSL#3) prevent endothelial dysfunction in rats with portal hypertension: Role of the angiotensin system. PLoS One. 9:e974582014. View Article : Google Scholar : PubMed/NCBI
97.	Fotiadis CI, Stoidis CN, Spyropoulos BG and Zografos ED: Role of probiotics, prebiotics and synbiotics in chemoprevention for colorectal cancer. World J Gastroenterol. 14:6453–6457. 2008. View Article : Google Scholar : PubMed/NCBI
98.	Sobhani I, Amiot A, Le Baleur Y, Levy M, Auriault ML, Van Nhieu JT and Delchier JC: Microbial dysbiosis and colon carcinogenesis: Could colon cancer be considered a bacteria-related disease? Therap Adv Gastroenterol. 6:215–229. 2013. View Article : Google Scholar : PubMed/NCBI
99.	Zhang M, Fan X, Fang B, Zhu C, Zhu J and Ren F: Effects of Lactobacillus salivarius Ren on cancer prevention and intestinal microbiota in 1,2-dimethylhydrazine-induced rat model. J Microbiol. 53:398–405. 2015. View Article : Google Scholar : PubMed/NCBI
100.	Chen ZF, Ai LY, Wang JL, Ren LL, Yu YN, Xu J, Chen HY, Yu J, Li M, Qin WX, et al: Probiotics Clostridium butyricum and Bacillus subtilis ameliorate intestinal tumorigenesis. Future Microbiol. 10:1433–1445. 2015. View Article : Google Scholar : PubMed/NCBI
101.	Russo F, Linsalata M and Orlando A: Probiotics against neoplastic transformation of gastric mucosa: Effects on cell proliferation and polyamine metabolism. World J Gastroenterol. 20:13258–13272. 2014. View Article : Google Scholar : PubMed/NCBI
102.	Cousin FJ, Jouan-Lanhouet S, Dimanche-Boitrel MT, Corcos L and Jan G: Milk fermented by Propionibacterium freudenreichii induces apoptosis of HGT-1 human gastric cancer cells. PLoS One. 7:e318922012. View Article : Google Scholar : PubMed/NCBI
103.	Linsalata M, Cavallini A, Messa C, Orlando A, Refolo MG and Russo F: Lactobacillus rhamnosus GG influences polyamine metabolism in HGC-27 gastric cancer cell line: A strategy toward nutritional approach to chemoprevention of gastric cancer. Curr Pharm Des. 16:847–853. 2010. View Article : Google Scholar : PubMed/NCBI
104.	Haghshenas B, Abdullah N, Nami Y, Radiah D, Rosli R and Khosroushahi AY: Different effects of two newly-isolated probiotic Lactobacillus plantarum 15HN and Lactococcus lactis subsp. Lactis 44Lac strains from traditional dairy products on cancer cell lines. Anaerobe. 30:51–59. 2014. View Article : Google Scholar : PubMed/NCBI
105.	Chitapanarux I, Chitapanarux T, Traisathit P, Kudumpee S, Tharavichitkul E and Lorvidhaya V: Randomized controlled trial of live Lactobacillus acidophilus plus Bifidobacterium bifidum in prophylaxis of diarrhea during radiotherapy in cervical cancer patients. Radiat Oncol. 5:312010. View Article : Google Scholar : PubMed/NCBI
106.	Osterlund P, Ruotsalainen T, Korpela R, Saxelin M, Ollus A, Valta P, Kouri M, Elomaa I and Joensuu H: Lactobacillus supplementation for diarrhoea related to chemotherapy of colorectal cancer: A randomised study. Br J Cancer. 97:1028–1034. 2007. View Article : Google Scholar : PubMed/NCBI
107.	Crouzet L, Rigottier-Gois L and Serror P: Potential use of probiotic and commensal bacteria as non-antibiotic strategies against vancomycin-resistant enterococci. FEMS Microbiol Lett. 362:fnv0122015. View Article : Google Scholar : PubMed/NCBI
108.	Gill EE, Franco OL and Hancock RE: Antibiotic adjuvants: Diverse strategies for controlling drug-resistant pathogens. Chem Biol Drug Des. 85:56–78. 2015. View Article : Google Scholar : PubMed/NCBI
109.	Cano-Garrido O, Seras-Franzoso J and Garcia-Fruitós E: Lactic acid bacteria: Reviewing the potential of a promising delivery live vector for biomedical purposes. Microb Cell Fact. 14:1372015. View Article : Google Scholar : PubMed/NCBI
110.	Mohamadzadeh M and Owen JL: Reprogramming intestinal immunity is the answer to induced pathogenic inflammation. Immunotherapy. 3:1415–1417. 2011. View Article : Google Scholar : PubMed/NCBI
111.	Wells JM and Mercenier A: Mucosal delivery of therapeutic and prophylactic molecules using lactic acid bacteria. Nat Rev Microbiol. 6:349–362. 2008. View Article : Google Scholar : PubMed/NCBI
112.	Bermúdez-Humarán LG: Lactococcus lactis as a live vector for mucosal delivery of therapeutic proteins. Hum Vaccin. 5:264–267. 2009. View Article : Google Scholar : PubMed/NCBI
113.	Marelli B, Perez AR, Banchio C, de Mendoza D and Magni C: Oral immunization with live Lactococcus lactis expressing rotavirus VP8 subunit induces specific immune response in mice. J Virol Methods. 175:28–37. 2011. View Article : Google Scholar : PubMed/NCBI
114.	Konturek PC, Sliwowski Z, Koziel J, Ptak-Belowska A, Burnat G, Brzozowski T and Konturek SJ: Probiotic bacteria Escherichia coli strain Nissle 1917 attenuates acute gastric lesions induced by stress. J Physiol Pharmacol. 60(Suppl 6): S41–S48. 2009.
115.	Spivak MIa, Lazarenko LM, Falalieieva TM, Virchenko OV and Neporada KS: Prophylactic effect of probiotic strains Bifidobacterium animalis VKL and VKB on stress-induced lesions in the gastric mucosa of rats. Fiziol Zh. 59:23–30. 2013.(In Ukrainian). PubMed/NCBI
116.	Nagaoka M, Hashimoto S, Watanabe T, Yokokura T and Mori Y: Anti-ulcer effects of lactic acid bacteria and their cell wall polysaccharides. Biol Pharm Bull. 17:1012–1017. 1994. View Article : Google Scholar : PubMed/NCBI
117.	Viggiano D, Ianiro G, Vanella G, Bibbò S, Bruno G, Simeone G and Mele G: Gut barrier in health and disease: Focus on childhood. Eur Rev Med Pharmacol Sci. 19:1077–1085. 2015.PubMed/NCBI
118.	Laine L, Takeuchi K and Tarnawski A: Gastric mucosal defense and cytoprotection: Bench to bedside. Gastroenterology. 135:41–60. 2008. View Article : Google Scholar : PubMed/NCBI
119.	Takeeda M, Hayashi Y, Yamato M, Murakami M and Takeuchi K: Roles of endogenous prostaglandins and cyclooxygenase izoenzymes in mucosal defense of inflamed rat stomach. J Physiol Pharmacol. 55:193–205. 2004.PubMed/NCBI
120.	Boirivant M and Strober W: The mechanism of action of probiotics. Curr Opin Gastroenterol. 23:679–692. 2007. View Article : Google Scholar : PubMed/NCBI
121.	Vieira AT, Teixeira MM and Martins FS: The role of probiotics and prebiotics in inducing gut immunity. Front Immunol. 4:4452013. View Article : Google Scholar : PubMed/NCBI
122.	Jones SE and Versalovic J: Probiotic Lactobacillus reuteri biofilms produce antimicrobial and anti-inflammatory factors. BMC Microbiol. 9:352009. View Article : Google Scholar : PubMed/NCBI
123.	Coman MM, Verdenelli MC, Cecchini C, Silvi S, Orpianesi C, Boyko N and Cresci A: In vitro evaluation of antimicrobial activity of Lactobacillus rhamnosus IMC 501^®, Lactobacillus paracasei IMC 502^® and SYNBIO^® against pathogens. J Appl Microbiol. 117:518–527. 2014. View Article : Google Scholar : PubMed/NCBI
124.	Bernet MF, Brassart D, Neeser JR and Servin AL: Lactobacillus acidophilus LA 1 binds to cultured human intestinal cell lines and inhibits cell attachment and cell invasion by enterovirulent bacteria. Gut. 35:483–489. 1994. View Article : Google Scholar : PubMed/NCBI
125.	Mukai T, Asasaka T, Sato E, Mori K, Matsumoto M and Ohori H: Inhibition of binding of Helicobacter pylori to the glycolipid receptors by probiotic Lactobacillus reuteri. FEMS Immunol Med Microbiol. 32:105–110. 2002. View Article : Google Scholar : PubMed/NCBI
126.	Lin YP, Thibodeaux CH, Peña JA, Ferry GD and Versalovic J: Probiotic Lactobacillus reuteri suppress proinflammatory cytokines via c-Jun. Inflamm Bowel Dis. 14:1068–1083. 2008. View Article : Google Scholar : PubMed/NCBI
127.	Takagi A, Matsuzaki T, Sato M, Nomoto K, Morotomi M and Yokokura T: Enhancement of natural killer cytotoxicity delayed murine carcinogenesis by a probiotic microorganism. Carcinogenesis. 22:599–605. 2001. View Article : Google Scholar : PubMed/NCBI
128.	Haller D, Bode C, Hammes WP, Pfeifer AM, Schiffrin EJ and Blum S: Non-pathogenic bacteria elicit a differential cytokine response by intestinal epithelial cell/leucocyte co-cultures. Gut. 47:79–87. 2000. View Article : Google Scholar : PubMed/NCBI
129.	Borchers AT, Selmi C, Meyers FJ, Keen CL and Gershwin ME: Probiotics and immunity. J Gastroenterol. 44:26–46. 2009. View Article : Google Scholar : PubMed/NCBI
130.	Madsen K, Cornish A, Soper P, McKaigney C, Jijon H, Yachimec C, Doyle J, Jewell L and De Simone C: Probiotic bacteria enhance murine and human intestinal epithelial barrier function. Gastroenterology. 121:580–591. 2001. View Article : Google Scholar : PubMed/NCBI
131.	Gotteland M, Cruchet S and Verbeke S: Effect of Lactobacillus ingestion on the gastrointestinal mucosal barrier alterations induced by indomethacin in humans. Aliment Pharmacol Ther. 15:11–17. 2001. View Article : Google Scholar : PubMed/NCBI
132.	Rao RK and Samak G: Protection and Restitution of Gut Barrier by Probiotics: Nutritional and clinical implications. Curr Nutr Food Sci. 9:99–107. 2013. View Article : Google Scholar : PubMed/NCBI
133.	Gomi A, Harima-Mizusawa N, Shibahara-Sone H, Kano M, Miyazaki K and Ishikawa F: Effect of Bifidobacterium bifidum BF-1 on gastric protection and mucin production in an acute gastric injury rat model. J Dairy Sci. 96:832–837. 2013. View Article : Google Scholar : PubMed/NCBI
134.	Dai C, Zhao DH and Jiang M: VSL#3 probiotics regulate the intestinal epithelial barrier in vivo and in vitro via the p38 and ERK signaling pathways. Int J Mol Med. 29:202–208. 2012.PubMed/NCBI
135.	Mennigen R, Nolte K, Rijcken E, Utech M, Loeffler B, Senninger N and Bruewer M: Probiotic mixture VSL#3 protects the epithelial barrier by maintaining tight junction protein expression and preventing apoptosis in a murine model of colitis. Am J Physiol Gastrointest Liver Physiol. 296:G1140–G1149. 2009. View Article : Google Scholar : PubMed/NCBI
136.	Wang FY, Liu JM, Luo HH, Liu AH and Jiang Y: Potential protective effects of Clostridium butyricum on experimental gastric ulcers in mice. World J Gastroenterol. 21:8340–8351. 2015. View Article : Google Scholar : PubMed/NCBI
137.	Virchenko OV, Falalyeyeva TM, Beregova TV, Spivak MY, Lazarenko LM and Demchenko OM: Effects of mono-, poly- and composite probiotics on the ulceration caused by restraint stress. Fiziol Zh. 61:35–41. 2015.(In Ukrainian). PubMed/NCBI
138.	Virchenko OV, Falalyeyeva TM, Beregova TV and Maryana SY: The multistrain probiotic enhances the healing process of stress-induced lesions of the gastric mucosa of rats. RJPBCS. 6:2492015.
139.	Wang JY, Yamasaki S, Takeuchi K and Okabe S: Delayed healing of acetic acid-induced gastric ulcers in rats by indomethacin. Gastroenterology. 96:393–402. 1989.PubMed/NCBI
140.	Santucci L, Fiorucci S, Di Matteo FM and Morelli A: Role of tumor necrosis factor alpha release and leukocyte margination in indomethacin-induced gastric injury in rats. Gastroenterology. 108:393–401. 1995. View Article : Google Scholar : PubMed/NCBI
141.	Yoshikawa T, Takano H, Naito Y, Oyamada H, Ueda S and Kondo M: Augmentative effects of tumor necrosis factor-alpha (human, natural type) on polymorphonuclear leukocyte-derived superoxide generation induced by various stimulants. Int J Immunopharmacol. 14:1391–1398. 1992. View Article : Google Scholar : PubMed/NCBI
142.	Senol A, Işler M, Karahan AG, Kiliç GB, Kuleaşan H, Gören I, Saritaş U, Kaya S, Cırış M, Aktürk O, et al: Effect of probiotics on aspirin-induced gastric mucosal lesions. Turk J Gastroenterol. 22:18–26. 2011. View Article : Google Scholar : PubMed/NCBI
143.	Senol A, Isler M, Karahan AG, Kilic GB, Kuleasan H, Kaya S, Keskin M, Goren I, Saritas U, Aridogan BC and Delibas N: Preventive effect of probiotics and α-tocopherol on ethanol-induced gastric mucosal injury in rats. J Med Food. 14:173–179. 2011. View Article : Google Scholar : PubMed/NCBI
144.	Allen A and Pearson JP: Mucus glycoproteins of the normal gastrointestinal tract. Eur J Gastroenterol Hepatol. 5:193–199. 1993. View Article : Google Scholar
145.	Wong WM, Poulsom R and Wright NA: Trefoil peptides. Gut. 44:890–895. 1999. View Article : Google Scholar : PubMed/NCBI
146.	Phillipson M, Johansson ME, Henriksnäs J, Petersson J, Gendler SJ, Sandler S, Persson AE, Hansson GC and Holm L: The gastric mucus layers: Constituents and regulation of accumulation. Am J Physiol Gastrointest Liver Physiol. 295:G806–G812. 2008. View Article : Google Scholar : PubMed/NCBI
147.	Corfield AP, Carroll D, Myerscough N and Probert CS: Mucins in the gastrointestinal tract in health and disease. Front Biosci. 6:D1321–D1357. 2001. View Article : Google Scholar : PubMed/NCBI
148.	Singh PK and Hollingsworth MA: Cell surf ace-associated mucins in signal transduction. Trends Cell Biol. 16:467–476. 2006. View Article : Google Scholar : PubMed/NCBI
149.	Karam SM, Tomasetto C and Rio MC: Trefoil factor 1 is required for the commitment programme of mouse oxyntic epithelial progenitors. Gut. 53:1408–1415. 2004. View Article : Google Scholar : PubMed/NCBI
150.	Ren JL, Luo JY, Lu YP, Wang L and Shi HX: Relationship between trefoil factor 1 expression and gastric mucosa injuries and gastric cancer. World J Gastroenterol. 11:2674–2677. 2005. View Article : Google Scholar : PubMed/NCBI
151.	Fu T, Kalbacher H and Hoffmann W: TFF1 is differentially expressed in stationary and migratory rat gastric epithelial cells (RGM-1) after in vitro wounding: Influence of TFF1 RNA interference on cell migration. Cell Physiol Biochem. 32:997–1010. 2013. View Article : Google Scholar : PubMed/NCBI
152.	Atuma C, Strugala V, Allen A and Holm L: The adherent gastrointestinal mucus gel layer: Thickness and physical state in vivo. Am J Physiol Gastrointest Liver Physiol. 280:G922–G929. 2001.PubMed/NCBI
153.	Kaunitz JD: Barrier function of gastric mucus. Keio J Med. 2:63–68. 1999. View Article : Google Scholar
154.	Mattar AF, Teitelbaum DH, Drongowski RA, Yongyi F, Harmon CM and Coran AG: Probiotics up-regulate MUC-2 mucin gene expression in a Caco-2 cell-culture model. Pediatr Surg Int. 18:586–590. 2002. View Article : Google Scholar : PubMed/NCBI
155.	Kim Y, Kim SH, Whang KY, Kim YJ and Oh S: Inhibition of Escherichia coli O157:H7 attachment by interactions between lactic acid bacteria and intestinal epithelial cells. J Microbiol Biotechnol. 18:1278–1285. 2008.PubMed/NCBI
156.	Otte JM and Podolsky DK: Functional modulation of enterocytes by gram-positive and gram-negative microorganisms. Am J Physiol Gastrointest Liver Physiol. 286:G613–G626. 2004. View Article : Google Scholar : PubMed/NCBI
157.	Caballero-Franco C, Keller K, De Simone C and Chadee K: The VSL#3 probiotic formula induces mucin gene expression and secretion in colonic epithelial cells. Am J Physiol Gastrointest Liver Physiol. 292:G315–G322. 2007. View Article : Google Scholar : PubMed/NCBI
158.	Ouwehand AC, Salminen S, Tölkkö S, Roberts P, Ovaska J and Salminen E: Resected human colonic tissue: New model for characterizing adhesion of lactic acid bacteria. Clin Diagn Lab Immunol. 9:184–186. 2002.PubMed/NCBI
159.	Nishiyama K, Nakamata K, Ueno S, Terao A, Aryantini NP, Sujaya IN, Fukuda K, Urashima T, Yamamoto Y and Mukai T: Adhesion properties of Lactobacillus rhamnosus mucus-binding factor to mucin and extracellular matrix proteins. Biosci Biotechnol Biochem. 79:271–279. 2015. View Article : Google Scholar : PubMed/NCBI
160.	Karam SM and Leblond CP: Dynamics of epithelial cells in the corpus of the mouse stomach. I.dentification of proliferative cell types and pinpointing of the stem cell. Anat Rec. 236:259–279. 1993. View Article : Google Scholar : PubMed/NCBI
161.	Karam SM, Straiton T, Hassan WM and Leblond CP: Defining epithelial cell progenitors in the human oxyntic mucosa. Stem Cells. 21:322–336. 2003. View Article : Google Scholar : PubMed/NCBI
162.	Karam SM: A focus on parietal cells as a renewing cell population. World J Gastroenterol. 16:538–546. 2010. View Article : Google Scholar : PubMed/NCBI
163.	Risau W: Mechanisms of angiogenesis. Nature. 386:671–674. 1997. View Article : Google Scholar : PubMed/NCBI
164.	Taketani Y, Kinugasa K, Kitajima R, Nishiumi S, Ashida H, Nakamura H, Fujita T, Kanzaki K, Masutani H and Yodoi J: Protective effects of oral administration of yeast thioredoxin against gastric mucosal injury. Biosci Biotechnol Biochem. 78:1221–1230. 2014. View Article : Google Scholar : PubMed/NCBI
165.	Schöttker B, Adamu MA, Weck MN and Brenner H: Helicobacter pylori infection is strongly associated with gastric and duodenal ulcers in a large prospective study. Clin Gastroenterol Hepatol. 10:487–493.e1. 2012. View Article : Google Scholar : PubMed/NCBI
166.	Cover TL and Blaser MJ: Helicobacter pylori in health and disease. Gastroenterology. 136:1863–1873. 2009. View Article : Google Scholar : PubMed/NCBI
167.	Vergara M, Catalán M, Gisbert JP and Calvet X: Meta-analysis: Role of Helicobacter pylori eradication in the prevention of peptic ulcer in NSAID users. Aliment Pharmacol Ther. 21:1411–1418. 2005. View Article : Google Scholar : PubMed/NCBI
168.	Malfertheiner P, Selgrad M and Bornschein J: Helicobacter pylori: Clinical management. Curr Opin Gastroenterol. 28:608–614. 2012. View Article : Google Scholar : PubMed/NCBI
169.	Giorgio F, Principi M, De Francesco V, Zullo A, Losurdo G, Di Leo A and Ierardi E: Primary clarithromycin resistance to Helicobacter pylori: Is this the main reason for triple therapy failure? World J Gastrointest Pathophysiol. 4:43–46. 2013. View Article : Google Scholar : PubMed/NCBI
170.	Graham DY and Fischbach L: Helicobacter pylori treatment in the era of increasing antibiotic resistance. Gut. 59:1143–1153. 2010. View Article : Google Scholar : PubMed/NCBI
171.	Papastergiou V, Georgopoulos SD and Karatapanis S: Treatment of Helicobacter pylori infection: Meeting the challenge of antimicrobial resistance. World J Gastroenterol. 20:9898–9911. 2014. View Article : Google Scholar : PubMed/NCBI
172.	Tongtawee T, Dechsukhum C, Leeanansaksiri W, Kaewpitoon S, Kaewpitoon N, Loyd RA, Matrakool L and Panpimanmas S: Improved Helicobacter pylori eradication rate of tailored triple therapy by adding Lactobacillus delbrueckii and Streptococcus thermophilus in northeast region of Thailand: A prospective randomized controlled clinical trial. Gastroenterol Res Pract. 2015:5180182015. View Article : Google Scholar : PubMed/NCBI
173.	Johnson-Henry KC, Mitchell DJ, Avitzur Y, Galindo-Mata E, Jones NL and Sherman PM: Probiotics reduce bacterial colonization and gastric inflammation in H. pylori-infected mice. Dig Dis Sci. 49:1095–1102. 2004. View Article : Google Scholar : PubMed/NCBI
174.	Sheu BS, Wu JJ, Lo CY, Wu HW, Chen JH, Lin YS and Lin MD: Impact of supplement with Lactobacillus- and Bifidobacterium-containing yogurt on triple therapy for Helicobacter pylori eradication. Aliment Pharmacol Ther. 16:1669–1675. 2002. View Article : Google Scholar : PubMed/NCBI
175.	Ushiyama A, Tanaka K, Aiba Y, Shiba T, Takagi A, Mine T and Koga Y: Lactobacillus gasseri OLL2716 as a probiotic in clarithromycin-resistant Helicobacter pylori infection. J Gastroenterol Hepatol. 18:986–991. 2003. View Article : Google Scholar : PubMed/NCBI
176.	Chenoll E, Casinos B, Bataller E, Astals P, Echevarría J, Iglesias JR, Balbarie P, Ramón D and Genovés S: Novel probiotic Bifidobacterium bifidum CECT 7366 strain active against the pathogenic bacterium Helicobacter pylori. Appl Environ Microbiol. 77:1335–1343. 2011. View Article : Google Scholar : PubMed/NCBI
177.	Gotteland M and Cruchet S: Suppressive effect of frequent ingestion of Lactobacillus johnsonii La1 on Helicobacter pylori colonization in asymptomatic volunteers. J Antimicrob Chemother. 51:1317–1319. 2003. View Article : Google Scholar : PubMed/NCBI
178.	Kabir AM, Aiba Y, Takagi A, Kamiya S, Miwa T and Koga Y: Prevention of Helicobacter pylori infection by lactobacilli in a gnotobiotic murine model. Gut. 41:49–55. 1997. View Article : Google Scholar : PubMed/NCBI
179.	Lesbros-Pantoflickova D, Corthésy-Theulaz I and Blum AL: Helicobacter pylori and probiotics. J Nutr. 137(3 Suppl 2): S812–S818. 2007.
180.	Ruggiero P: Use of probiotics in the fight against Helicobacter pylori. World J Gastrointest Pathophysiol. 5:384–391. 2014. View Article : Google Scholar : PubMed/NCBI
181.	Yang YJ and Sheu BS: Probiotics-containing yogurts suppress Helicobacter pylori load and modify immune response and intestinal microbiota in the Helicobacter pylori-infected children. Helicobacter. 17:297–304. 2012. View Article : Google Scholar : PubMed/NCBI
182.	Sgouras D, Maragkoudakis P, Petraki K, Martinez-Gonzalez B, Eriotou E, Michopoulos S, Kalantzopoulos G, Tsakalidou E and Mentis A: In vitro and in vivo inhibition of Helicobacter pylori by Lactobacillus casei strain Shirota. Appl Environ Microbiol. 70:518–526. 2004. View Article : Google Scholar : PubMed/NCBI
183.	Aiba Y, Nakano Y, Koga Y, Takahashi K and Komatsu Y: A highly acid-resistant novel strain of Lactobacillus johnsonii No. 1088 has antibacterial activity, including that against Helicobacter pylori, and inhibits gastrin-mediated acid production in mice. Microbiologyopen. 4:465–474. 2015. View Article : Google Scholar : PubMed/NCBI
184.	Isobe H, Nishiyama A, Takano T, Higuchi W, Nakagawa S, Taneike I, Fukushima Y and Yamamoto T: Reduction of overall Helicobacter pylori colonization levels in the stomach of Mongolian gerbil by Lactobacillus johnsonii La1 (LC1) and its in vitro activities against H. pylori motility and adherence. Biosci Biotechnol Biochem. 76:850–852. 2012. View Article : Google Scholar : PubMed/NCBI
185.	Hsieh PS, Tsai YC, Chen YC, Teh SF, Ou CM and King VA: Eradication of Helicobacter pylori infection by the probiotic strains Lactobacillus johnsonii MH-68 and L. salivarius ssp. salicinius AP-32. Helicobacter. 17:466–477. 2012. View Article : Google Scholar : PubMed/NCBI
186.	Chen X, Liu XM, Tian F, Zhang Q, Zhang HP, Zhang H and Chen W: Antagonistic activities of lactobacilli against Helicobacter pylori growth and infection in human gastric epithelial cells. J Food Sci. 77:M9–M14. 2012. View Article : Google Scholar : PubMed/NCBI
187.	Mack DR, Ahrne S, Hyde L, Wei S and Hollingsworth MA: Extracellular MUC3 mucin secretion follows adherence of Lactobacillus strains to intestinal epithelial cells in vitro. Gut. 52:827–833. 2003. View Article : Google Scholar : PubMed/NCBI
188.	Thiraworawong T, Spinler JK, Werawatganon D, Klaikeaw N, Venable SF, Versalovic J and Tumwasorn S: Anti-inflammatory properties of gastric-derived Lactobacillus plantarum XB7 in the context of Helicobacter pylori infection. Helicobacter. 19:144–155. 2014. View Article : Google Scholar : PubMed/NCBI
189.	Hwang SW, Kim N, Kim JM, Huh CS, Ahn YT, Park SH, Shin CM, Park JH, Lee MK, Nam RH, et al: Probiotic suppression of the H. pylori-induced responses by conjugated linoleic acids in a gastric epithelial cell line. Prostaglandins Leukot Essent Fatty Acids. 86:225–231. 2012. View Article : Google Scholar : PubMed/NCBI
190.	Kim JM, Kim JS, Kim YJ, Oh YK, Kim IY, Chee YJ, Han JS and Jung HC: Conjugated linoleic acids produced by Lactobacillus dissociates IKK-gamma and Hsp90 complex in Helicobacter pylori-infected gastric epithelial cells. Lab Invest. 88:541–552. 2008. View Article : Google Scholar : PubMed/NCBI
191.	Lee JS, Paek NS, Kwon OS and Hahm KB: Anti-inflammatory actions of probiotics through activating suppressor of cytokine signaling (SOCS) expression and signaling in Helicobacter pylori infection: A novel mechanism. J Gastroenterol Hepatol. 25:194–202. 2010. View Article : Google Scholar : PubMed/NCBI
192.	Mehling H and Busjahn A: Non-viable Lactobacillus reuteri DSMZ 17648 (Pylopass™) as a new approach to Helicobacter pylori control in humans. Nutrients. 5:3062–3073. 2013. View Article : Google Scholar : PubMed/NCBI
193.	Holz C, Busjahn A, Mehling H, Arya S, Boettner M, Habibi H and Lang C: Significant reduction in Helicobacter pylori load in humans with non-viable Lactobacillus reuteri DSM17648: A pilot study. Probiotics Antimicrob Proteins. 7:91–100. 2015. View Article : Google Scholar : PubMed/NCBI
194.	Hauser G, Salkic N, Vukelic K, JajacKnez A and Stimac D: Probiotics for standard triple Helicobacter pylori eradication: A randomized, double-blind, placebo-controlled trial. Medicine (Baltimore). 94:e6852015. View Article : Google Scholar : PubMed/NCBI
195.	Francavilla R, Polimeno L, Demichina A, Maurogiovanni G, Principi B, Scaccianoce G, Ierardi E, Russo F, Riezzo G, Di Leo A, et al: Lactobacillus reuteri strain combination in Helicobacter pylori infection: A randomized, double-blind, placebo-controlled study. J Clin Gastroenterol. 48:407–413. 2014.PubMed/NCBI
196.	Pantoflickova D, Corthésy-Theulaz I, Dorta G, Stolte M, Isler P, Rochat F, Enslen M and Blum AL: Favourable effect of regular intake of fermented milk containing Lactobacillus johnsonii on Helicobacter pylori associated gastritis. Aliment Pharmacol Ther. 18:805–813. 2003. View Article : Google Scholar : PubMed/NCBI
197.	Michetti P, Dorta G, Wiesel PH, Brassart D, Verdu E, Herranz M, Felley C, Porta N, Rouvet M, Blum AL and Corthésy-Theulaz I: Effect of whey-based culture supernatant of Lactobacillus acidophilus (johnsonii) La1 on Helicobacter pylori infection in humans. Digestion. 60:203–209. 1999. View Article : Google Scholar : PubMed/NCBI
198.	Szajewska H, Horvath A and Piwowarczyk A: Meta-analysis: The effects of Saccharomyces boulardii supplementation on Helicobacter pylori eradication rates and side effects during treatment. Aliment Pharmacol Ther. 32:1069–1079. 2010. View Article : Google Scholar : PubMed/NCBI
199.	Zou J, Dong J and Yu X: Meta-analysis: Lactobacillus containing quadruple therapy versus standard triple first-line therapy for Helicobacter pylori eradication. Helicobacter. 14:97–107. 2009. View Article : Google Scholar : PubMed/NCBI
200.	Hamilton-Miller JM: The role of probiotics in the treatment and prevention of Helicobacter pylori infection. Int J Antimicrob Agents. 22:360–366. 2003. View Article : Google Scholar : PubMed/NCBI
201.	Patel A, Shah N and Prajapati JB: Clinical application of probiotics in the treatment of Helicobacter pylori infection - a brief review. J Microbiol Immunol Infect. 47:429–437. 2014. View Article : Google Scholar : PubMed/NCBI
202.	Shane AL, Cabana MD, Vidry S, Merenstein D, Hummelen R, Ellis CL, Heimbach JT, Hempel S, Lynch SV, Sanders ME and Tancredi DJ: Guide to designing, conducting, publishing and communicating results of clinical studies involving probiotic applications in human participants. Gut Microbes. 1:243–253. 2010. View Article : Google Scholar : PubMed/NCBI